cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy that involves harvesting bone marrow stem cells from patients ...
This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first in the Middle East to approve Casgevy for the treatment of SCD and TDT. The ...